Long-term results of organ transplantation remain unsatisfactory, mainly because of chronic rejection and complications associated with immunosuppressive medications. Swedish biopharma ITBMed AB is developing a humanized anti-CD2 monoclonal antibody, siplizumab (formerly known as MEDI-507), that has shown promise in a Phase II study in HLA-mismatched kidney transplant patients can achieve tolerance of the transplanted organs with the need for lifelong immunosuppression.
ITBMed has raised $67m, led by Pablo Legoretta, the founder and CEO of Royalty Pharma, to further develop the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
